504530968 09/01/2017

### PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4577674

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

### **CONVEYING PARTY DATA**

Name	Execution Date
CYPRESS BIOSCIENCE INC.	08/29/2017

### **RECEIVING PARTY DATA**

Name:	EXAGEN DIAGNOSTICS, INC.
Street Address:	1261 LIBERTY WAY
Internal Address:	SUITE C
City:	VISTA
State/Country:	CALIFORNIA
Postal Code:	92081

### **PROPERTY NUMBERS Total: 11**

Property Type	Number
Patent Number:	7582282
Patent Number:	7695908
Patent Number:	6921667
Patent Number:	7563590
Patent Number:	7361517
Patent Number:	7585640
Patent Number:	8080382
Patent Number:	7588905
Patent Number:	8126654
Patent Number:	7390631
Patent Number:	8999921

### **CORRESPONDENCE DATA**

**Fax Number:** (312)913-0002

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 312 913 0001
Email: allen@mbhb.com

Correspondent Name: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP

Address Line 1: 300 SOUTH WACKER DRIVE, SUITE 3100

Address Line 4: CHICAGO, ILLINOIS 60606

PATENT

504530968 REEL: 043747 FRAME: 0382

NAME OF SUBMITTER:	DAVID HARPER
SIGNATURE:	/David Harper/
DATE SIGNED:	09/01/2017

### **Total Attachments: 26**

source=ConfirmationofTerminationofPatents\_asfiled#page1.tif source=ConfirmationofTerminationofPatents asfiled#page2.tif source=ConfirmationofTerminationofPatents asfiled#page3.tif source=ConfirmationofTerminationofPatents\_asfiled#page4.tif source=ConfirmationofTerminationofPatents asfiled#page5.tif source=ConfirmationofTerminationofPatents asfiled#page6.tif source=ConfirmationofTerminationofPatents\_asfiled#page7.tif source=ConfirmationofTerminationofPatents\_asfiled#page8.tif source=ConfirmationofTerminationofPatents asfiled#page9.tif source=ConfirmationofTerminationofPatents asfiled#page10.tif source=ConfirmationofTerminationofPatents\_asfiled#page11.tif source=ConfirmationofTerminationofPatents asfiled#page12.tif source=ConfirmationofTerminationofPatents asfiled#page13.tif source=ConfirmationofTerminationofPatents asfiled#page14.tif source=ConfirmationofTerminationofPatents asfiled#page15.tif source=ConfirmationofTerminationofPatents asfiled#page16.tif source=ConfirmationofTerminationofPatents asfiled#page17.tif source=ConfirmationofTerminationofPatents asfiled#page18.tif source=ConfirmationofTerminationofPatents\_asfiled#page19.tif source=ConfirmationofTerminationofPatents asfiled#page20.tif source=ConfirmationofTerminationofPatents asfiled#page21.tif source=ConfirmationofTerminationofPatents asfiled#page22.tif source=ConfirmationofTerminationofPatents asfiled#page23.tif source=ConfirmationofTerminationofPatents asfiled#page24.tif source=ConfirmationofTerminationofPatents\_asfiled#page25.tif source=ConfirmationofTerminationofPatents asfiled#page26.tif

> PATENT REEL: 043747 FRAME: 0383

### TERMINATION OF SECURITY INTEREST IN TRADEMARKS AND PATENTS

WHEREAS Exagen Diagnostics, Inc., a Delaware corporation with a principal office at 1261 Liberty Way, Suite C, Vista, CA 92081 (the "Grantor"), is the owner or licensee of record of the trademarks and applications, now issued or pending in the United States Patent and Trademark Office; and is the owner of record of the patents and patent applications **B**, now issued or pending in the United States Patent and Trademark Office (collectively the "IP"), listed in Exhibit A; and

WHEREAS, the Grantor entered into that certain Security Agreement dated as of October 12, 2010 (the "Security Agreement"), between the Grantor and Royalty Pharma Collection Trust ("Secured Party"), as successor to Cypress Bioscience Inc. ("Cypress"), formerly having a place of business at 4350 Executive Drive, Suite 325, San Diego, California 92121, a true and correct copy of which was recorded by the United States Patent and Trademark Office on June 2, 2010, at Reel 025126, Frame 0245;

WHEREAS, the Secured Party's assets were acquired by the Grantor on October 8, 2010;

WHEREAS, in 2011 Cypress was dissolved and the Secured Party succeeded to all of the Cypress's assets;

WHEREAS Grantor represents that the Note that was secured by the IP, as well the other conditions to release of the security interest in Amendment Number 4 to the Asset Purchase Agreement between Grantor and the Secured Party, executed on October 8, 2013, have been satisfied;

WHEREAS, the Secured Party desires to release its security interest in the IP and terminate the Security Agreement;

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Secured Party hereby:

- 1. releases and reassigns to the Grantor any and all liens, security interests, right, title and interest of Secured Party pursuant to the Security Agreement in the IP more fully described on Exhibit A, without recourse or representation or warranty, express or implied; and
- 2. authorizes and requests the Commissioner of Patents and Trademarks of the United States of America to note and record the existence of the release hereby given.

IN WITNESS WHEREOF, Secured Party has caused this Termination of Security Interest in Trademarks and Patents to be signed by its duly authorized representative as of this 29th day of August 2017.

Secured Party:

Royalty Pharma Collection Trust,

As successor to Cypress Bioscience Inc.

Lange W. Stoyd

By: RP Management, LLC, As Administrator of Royalty Pharma Collection Trust

Name: George W. Lloyd

Title: EVP & General Counsel

# SCHEDULEA

Status	EXPIRED	EXHIBED	CAUCING	BXPIRED	EXPIRED	PENDING	NATTOWAL PHASE DUE 10/22/2010	CXPIREST
fssue Date/Publication Date						004-22-43/09		
Patent Nu./Publication No.						2009/0265 2118		
Filing Date	Jun-20-2008	8008.3008	Aum-21-2010	3/01-04-2008	Apr-22-3008	Apr.22-2009	Apr-22-2009	Sep-27-2007
7 N N N N N N N N N N N N N N N N N N N	255%,00119	61218,79	0.17384.770	61.032,849	770019	201428	PCT/US2009/ 041443	Z127566/199
	MARKERS ASSOCIATED WITH METHOTREXATE THERAPY	MARKERS ASSOCIATED WITH METHOTREXATE THERAPY	MARKERS ASSOCIATED WITH METHOTREXATE THERAPY	METHODS FOR QUANTIPYING METHOTREXAYE POLYGLUTAMATES USING TANDEM MASS SPECTROMETRY	PREDICTION OF AN INDIVIDUAL'S RISK OF DEVELOPING PHEUMATOID ARTHRITS	PREDICTION OF AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS	PREDICTION OF AN INDIVIDUAL'S RISK OF DEVELOPING RIBUMATOID ARTHRITS	IMPROVEMENTS IN METHODS FOR CALIBRATION OF DIAGNOSTIC INSTRUMENTATION
Cooley Attorney Docket No.	CYPR-044/00US	CYPR-044/0[1]S	CYPR-M4/02118	CYPR-035(m)/s	CYPR-027/00/US	CYPR-027/01US	CYPR-027/01/WO	CYPR-047000US

ij

Status	EXPIRED	EXPIRED.	PENDING	EXPIRED	
Date/Publication Date			***		
No. Patent No. Publication No.					*******************************
Filing Date	Sep-27-3007	Sep-27-2007	Mar-26-2010	May-01-2009	
Appla. No.	6(1/9)/5,714	912,739		28. 28. 28.	***************************************
Title	IMPROVED BUTFER, COMPOSITIONS FOR DIAGNOSTIC ASSAYS	COMPOSITIONS FOR USE AS DIAGNOSTIC ASSAY CONTROLS AND METHODS FOR PRODUCING SAME	METHODS AND COMPOSITIONS FOR IMPROYED DIACNOSTIC ASSAYS	PREDISPOSING GENOTYPE COMBINATIONS IN FOLATE AND ADENOSINE BIOSYNTHESIS	
Cooley Attorney Docket No.	CELLATOPE	CYPR-047/02LS CELLATOPE	CYPR-04703US	\$30001 \$4.0001	

08/8/12/8/89

0.88673.45.80

Coaley Attorney		-				The Confederate and the Confederate Confed
Jocket No.		Applin. No.	Filling Date	No./Publication No.	Bate/Publication Date	Status
27 PR-052 Annual S	CELL-BASED COMPLEMENT ACTIVATION PRODUCT ALGORITHM FOR DIACHOSING SYSTEMICLUPUS ER YHEMATOSUS	817252,62.6	5805-91 1-100			Nicka
BISPHOSPHONA TE CYPR-338/01US	COMPOSITIONS COMPRISING A BISPHOSPHONATE AND AN ANTIFOLATE	\$\frac{1}{2}\$	Fdt-422_23103	88.	Sup-27-23007	PENDING Non-Final Rejection nailed May-25-3010; response due Aug-25-
SAM-E A VPR-dationis	METHODS OF REDUCING MITS TOXICITY	\$17136,081	Aug-11-2008			EXPIRED
CYPR-84701 WO	METHODS AND COMPOSITIONS FOR IMPROVED DIAGNOSTIC ASSAYS	PCT/US2068/ 076302	Sept. 12, 2008			038010

Grantor has co-ownership rights under the following patents and the security interest granted pursuant to this IP Agreement extends only to Grantor's ownership interest in such patents:

		MATIONAL PHASE
B	2	
X PIRED	ONJONA.	Ě
		20
>	as a second	Ø\$
	000	
	0ct 16-2008	Dat-16-2008
		<u> </u>
¢1/105,865	888	PCT/1/52/00 9/hd/1085
S.		ŽŠ
9 9	9.5	9 0
í Pájs		
		227755
METHOD FOR DIA MONITORING OF: ACTIVITY AND RE- TREATMENT IN S'. LUPUS ERYTHEN. (SLE) AND OTHER AUTOIMMUNE DIE	METHOD FOR DIAGNOSIS / MONITORING OF DISEASE ACTIVITY AND RESPONSE REATMENT IN SYSTEMIC LUPUS ERYTHEMA TOSUS (SLE) AND OTHER AUTOIMMUNE DISEASES	METHOD FOR DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY AND RESPONSE TO FREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER
METHOD FOR DIAGNOSIS ANI MONITORING OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER AUTOIMMUNE DISEASES	METHOD FOR DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER AUTOIMMUNE DISEASES	METHOD FOR DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER
<u> </u>		
CYPR-048/09US METHOD FOR DIAGNOSIS AND CELLATOPE MONITORING OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER AUTOIMMUNE DISEASES	CPIRATOR	CYCPR- 048/01WC
ää	δÜ	ČŽ

රත්

## SCHEDULEC

Klampuist 8123-   DIAGNOSING AND MONITORING	AMONITORING 60/570,406			\$ \$28.50	
DIAGROSING AND MONITORING  INFLAMMATORY DISEASES BY MEASURING  DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING  DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	DISEASESBY	24.12.00 24.22.00 24.22.00 24.20.00 24.			Expired
DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	MONITORING PCT/US28/35/01 DISEASES BY 6436	\$000			National Filings in AU, CA, EP, IP
DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	JACASES BY	\$1.1.2008 \$			Pending
DIAGNOSING AND MONITORING INFLAMMA TORY DISEASES BY MEASURING INFLAMMA TORY DISEASES BY	7 MONITORING 2,564,492 DISEASES BY	80 80 80 80 80 80 80 80 80 80 80 80 80 8			Panding
DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING UNACHOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING INFLAMMATORY DISEASES BY MEASURING UNFLAMMATORY DISEASES BY MEASURING INFLAMMATORY DISEASES BY MEASURING UNACHOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING UNAGROSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING UNAGROSING AND MONITORING	FMONITORING 574794X.3 DISEASES BY	e e e e			Pending
DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING INFLAMMATORY DISEASES BY MEASURING INFLAMMATORY DISEASES BY MEASURING DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING DIAGNOSING AND MONITORING	OISEASES BY	\$1175			Fonding
DIAGNOSING AND MONITORING IMFLAMMA TORY DISEASES BY MEASURING DIAGNOSING AND MONITORING INFLAMMA TORY DISEASES BY MEASURING DIAGNOSING AND MONITORING INFLAMMA TORY DISEASES BY	) MONITORING 10/345,052 DISEASES BY	10/10/2006	7,585,540	Š.	January Tananananananananananananananananananan
DIAGROSING AND MONITORING INFLAMMA TORY DISEASES BY MEASURING DIAGROSING AND MONITORING INFLAMMA TORY DISEASES BY	MOMITOWING 11/127,348 DISEASES BY	\$711/2003			Panding
DIAGNOSING AND MONITORING DIFLAMMA TORY DISPASPS BY		2002			Petroling.
	MONTOKRYG DISEASES BY	3000 0000 11.65			REGISTERED Validated in Belgium, Deturnark, Finland, France, Germany, Italy, Lucembourg, the Netherland, Spain, Sweden, Switzerhand, Intend Kinedom
Klarquist 8123- DIAGNOSING AND MONITORING 83085-12-BE INFLAMMATORY DISEASES BY MEASURING	MONITORING DISEASES BY				VALIDATED
Klarquist 8123- DIAGNOSING AND MONITORING					VALIDATED

CI8/\$472,4880

Patent Reel: 043746 Franc: 02896

	83095-13-13&	MEASURING MEASES BY						
DIACHOCSING AND MONITORING	Klarquist 8123- 83095-14-71	DIAGNOSING AND MONITOS INC INFLAMMATORY DISCASES BY MEASURING					VALIDATED	
DAGOVSPIG AND MONITORING	Klanpurst 8123- 83093-15-FR	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING					VALIDATED	Ţ
DIAGNOSING AND MONTTORING	Klerquist 8123- 83095-16-DE	DIAGNOSING AND MOMITORING INFLAMMATORY DISEASES BY MÉASURING					VALIDATED	T
PIAGNOSING AND MONITORING   PIAGNOSING AND MONITORING	Klarquist 8123- 83005-17-11	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING					VALIDATED	1
DIACINGSING AND MONITORING	Klarquist 81.23- 82095-18-1.11	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING					VALIDATED	1
DIAGNOSING AND MONITORING   NECESSES BY     INFLAMMATORY DISEASES BY	Klarquest 8123- 83008-19-N1	DIAGNOSING AND MONTORING INFLAMMATORY DISEASES BY MEASURING					VALIDATED	Ţ
DIAGNOSING AND MONITORING	Klarquist 8123- 83095-20-ES	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING					VALIDATED	Ţ
DIAGNOSING AND MONITORING	Klampulet 8123- 83008-21-SE	DIAGNOSING AND MONTORING INFLAMMATORY DISEASES BY MEASURING					VALIDATED	γ
DIACPLOSING AND MONITORING	Kilarquist 8123- 81095-22-CH	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING					VALIDATED	
DIACINOSING AND MONITORING   MEASURING     MEASURING   MEASURING   MONITORING OF	22.23 22.23 24.23 25.23 26.2	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING					VALIDATED	r
3- DIAGNOSIS & MONITORING OF 60/318,541 9/10/2001  SYSTEMIC LIPUS (PROVISIONAL)  1- DIAGNOSIS & MONITORING OF 2002/33/691 9/9/2002  3- DIAGNOSIS & MONITORING OF 2002/33/691 9/9/2002  3- DIAGNOSIS & MONITORING OF 2,460,189 9/9/2002  5- DIAGNOSIS & MONITORING OF 2,460,189 9/9/2002  5- DIAGNOSIS & MONITORING OF 2,260,189 9/9/2002  5- DIAGNOSIS & MONITORING OF 2,200,180 9/9/2002	#rquis# 8123- 095-24-HK	DIACHOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING					VALIDATED	ſ
3- DIAGNOSIS & MONITORING OF PCTLISSBU202 99/2002  1- SYSTEMIC LUPUS (PCT)  3- DIAGNOSIS & MONITORING OF 200333691 9/9/2002  3- DIAGNOSIS & MONITORING OF 2,460,189 9/9/2002  5- DIAGNOSIS & MONITORING OF 2,460,189 9/9/2002  5- DIAGNOSIS & MONITORING OF 2822148 6 9/9/2002	anquist 8123- 096-01-US	DIAGNOSIS & MONITORING DF SYSTEMIC LUPUS (PROVISIONAL)	18831809	10020176			Expired.	ŗ
3- DIAGNOSIS & MONITORING OF 2002323691 9/9/2002 2002323691 7/17/2008 5- DIAGNOSIS & MONITORING OF 2,460,189 9/9/2002 5- SYSTEMIC LUPUS (CANADA) 5- DIAGNOSIS & MONITORING OF 2,2148.6 9/9/2002	anquist 8123- 096-02-PCT	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (PCT)	# Tri \$20002402 \$910	2002/8/6			Compared	T
3- DJAGNOSIS & MONITORING OF 2,460,189 9/8/2002 SYSTEMIC LUPUS (CANADA) 3- DJAGNOSIS & MONITORING OF 2/8/22148/6 9/9/2002	impuist 8123- 098-03-AU	SYSTEMIC LUPUS (AUSTRALIA)		2002/8/6	2002323691	2/172038	T	T
4. DIAGNOSIS & MONITORING OF 2822148.6 9/9/2002		DIAGNOSIS & MOWITORING OF SYSTEMIC LUPUS (CANADA)	2,460.189	2002			%arprox.	<b></b>
		DIAGNOSIS & MONITORING OF	2822148.6	5000086			Attandence	<b> </b>

Paciding	SYSTEMIC LUPUS (CHINA)					
7.22/CHEVP20 999/2002  2003-726353  3.10/2004  AL  2009-197692  3.07/2002  3.09/2002  4  2.009-197692  3.07/2002  3.09/2002	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (EUROPE)	2757641.7	9%/2002			Ponding
2009-1976-92 2009-1976-92 2009-1976-92 31072008 31072008 31072008 31072008 31072008	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (INDIA)	722/CHENRIZO EL	200127678			To be Abandonia
AL 20002002941 7/3/2/008 7/2/008 7/2/2/008 7/2/2/008 7/2/2/008 7/2/2/008 7/2/2/008 7/2/2/2/008 7	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (JAPAN)	2003-526353	8/9/2002			Portuing
2000220022 20002-197692 20005-1	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (U.S. NATIONAL STAGE)	10/489.219	\$110200	23808 23808 23808	6724/2008	Technist .
2009-197892	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (AUSTRALIAN DIVISIONAL)	20008202944	**************************************			Fanding
	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (JAPAN DIVISIONAL)	200%-197692	20002000			Ponding
	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (BELGUIM)					Validoaried
	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (DENMARK)					VALIBATED
	DIAGNOSIS & MONITORING OF SYSTEMIC LUPIS (PINCAND)					VACIDATED
	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (PRANCE)					VALIDATED
	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (GRAMANY)					VALABATED
	DIACINOSIS & MONITORING OF SYSTEMIC LUPUS (ITALY)					VALIDATED
	DIAGROSIS & MONITORING OF SYSTEMIC LUPUS (LUXEMBOURG)					VALIDATED
	DIACNOSIS & MUNITORING OF SYSTEMIC LUPUS (THE NETHERLANDS)					VALIDATED
	DIACMOSIS & MONITORING OF SYSTEMIC LUPIS (NORWAY)					VALIDATED
	DIACINOSIS & MONITORING OF SYSTEMIC LUMIS (SPAIN)					VALIDATED
	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (SWEDEN)					VALIDATED
	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (SWITZERLAND)					VALIDATED
	DIAGNOSIS & MONITORING OF					VALIDATED

830%-13-DK Klarquist 8123-830%-16-18-1 Klarquist 8123-Klarquist 8123-830%-16-DE Klarquist 8123-Klarquist 8123-830%-18-11

bandoned

83096-05-CN Klampaist 8133-83096-06-EP Klampaist 8133-83096-07-IN Klampaist 8123-83096-08-IP Klampaist 8123-

Klerquist 8123-83096-11-JP

Klanguist 8123-87096-10-AU

Klarquist 8123-85196-13-8E Klarquist 8123-

Klarquist 8133-

Klampulat 8123-83096-20-NO

Klarquist 8123-81096-21-ES Klarquist 8123-81096-22-SE Klarquist 8123-83096-23-CH

Elampaist 8123-83096-19-NL

	TO SECOND	Completed	Pending	Zending	Pending	Pending	(Constant)	Pending	Expired	Entered National Phase	<b>1</b>	Permitting	(B&UED
							<b>X</b> 007 7007 8007 8007 8007 8007 8007 8007						4/21/2010
							2,588,94,5				2004249133		16.35692
	EU0.C91.7	* 88 88 88 88 88 88 88 88 88 88 88 88 88	<b>#</b> 116/200 <b>4</b>	<b>X</b>	4.00.00	\$ 3 3	86 27 27 27 27 27 27 27 27 27 27 27 27 27	\$772003	8/13/2003	2000 2000 2000	MICO 100	<b>4</b> 0.021.03	#00ZZZ
	60,463,447	F. 17.8.20 1.0.8.20 1	20042323007	2.423.24	4735986.5	#1. 118. 13.	LD 728.50	12/53%,0001	\$ 4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	PC1/A18S20044/01	200 M224W 200 M224W 200 M224W	# # # # # # # # # # # # # # # # # # #	4775460
	DIAGNOSIS AND MONTORING OF SYSTEMIC LUPUS ERYTHEMATOSUS	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS (PCT)	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERVITHEMATOSUS	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPIS ERYTHEMATORIS (ERC)	IDENTIFICATION AND MONITORING OF SYSTBMIC LUPUS ERYTHEMATOSLIS (JAPAN)	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS	IDENTIFICATION AND MONITORING OF SYSTEMIC	MONITORING IMMLINOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (US)	MONITORING BAMINOLOGIC. HEMATOLOGIC AND INILAMMATORY DISEASES (PCT)	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (AUSTRALIA)	MONITORING IMMUNOLOCIC. HEMATOLOCIC AND INFLAMMATORY DISEASES (CANADA)	MCMITORING IMMUNGLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES
830.98-24-(38	Klarqust 8123- 83097-01-US	Klanquist 8123- 83097-02-PCT	Kiarquist 8123- 83097-413-41J	Klarquist 8133- 83097-04-CA	Klanquist 8123- 83097-415-EPC	Klarquist 8123- 830v7-06-1P	Klanguist 8123- 83097-47-418	Klarguist 8123- Klarguist 83097- 08-1/3	Klamparet 8123- 83100-01-4/8	Klerquist 8123- 83100-422-PCT	Klanquis 8123- 83100-43-4U	Khrquet 8123- 83100-04-CA	Kimquist 8123- 831001-05-EP

7

Abandonad	Petroling	Pending	Tu De Abandaried	To Be Abatalousd	Possiting	OT STATE OF THE ST	Ponding	Yearding	Validated	Validated	Validated
						4/30/2008	1029/2004		B1027124	4,21,231,0	4/21/2019
						X (1033 (1033)			<b>3</b>	16356/2	1635692
4/13/23/04	W12/200	6/12/20004	6/12/2006/4	6122204	70,000	8/15/2008 8/15/2008	8/12/2004	2000 2000 2000 2000 2000 2000 2000 200	7 (5)	\$ 8 8	8/12/2004
13.2/CHEW6/20	88 72 12	200%-233.70%	10-2005- 7021933	<b>X4</b> 4223	2001 (2001)	<b>7</b> 28	10/866,509	100033 88 88 88 88 88 88 88 88 88 88 88 88 8		47.76460	4776460
	MONITORING IMMINOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES	MONITORING IMALINOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (TAPAN)	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (KOREA)	MANITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (NEW ZEALAND)	MONITORING BAMINOLOGIC. HEMATOLOGIC AND INFLAMMATORY DISBASES	MONITORING IMMINOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISBASES (SOUTH AFRICA)	MONTORING BAMUNOLOGIC HEMATOLOGIC AND INFLAMMATORY DISEASES (U.S.)	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (EPC)	MONITORING IMMI,NOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISPASES (BELGILM)	MONITORING IMMUNOLOGIC. HEMATOLOGIC AND INFLAMMATORY DISEASES DENMARK)	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND
Klarquist 8123- 83100-06-IN	Klanguist 81.23- 83100-07-45	Kismpuss 8.123- 8.3100-08-1P	Klarquset 8123- 83100-09-KR	Klarquid 8123- 83100-10-NZ	Klangurat 8123- 831001-11-20	Klarquist 8123- 8310fb12-SA	Klanquist 8123- 83100-13-415	Klarquist 8123- 83100-15-EPC	Kumpulst 8123- 83100-16-82	Kimquist 3123- 83100-17-DK	Klarquist 8123- 83100-18-Fi

G8/87.273882

Patent Reel: 043746 Franc: 02290

	IMPLAMMATORY DISEASES   (FINLAND)					
Klanquist 8123- 83100-1947R	MONITORING IMMUNOLOGIC. HEMATOLOGIC AND INFLAMMATORY DISEASES (FRANCE)	#4778/4050 #4000	<b>7</b> 0.00000000000000000000000000000000000	2388	4/21/2010 0.002/10	Validated
K.farquist 8123- 831(00-20-DE	MONITORING IMMUNCILOGIC. HEMATOLOGIC AND INFLAMMATORY DISEASES (OERMANY)	47.78468	27.200 27	-0% -0%	421.22810 2.22810	A Ministration
Kiarquist 8123- 63100-21-17	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (ITALY)	477648	### ### ### ### ### #### #############	769509	421/2010	Validated
Klarowsk 8123- 83100-22-LU	MONITORING INMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (LUXEMBOURG)	\$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	\$ 2.0 8	83	\$731/30 X	Validated
Klarquist 8123- 83100-23-NL	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (WETHERLANDS)	47778480	0.17.23.94 9.00.20.33.94	7.895(0)	#72172001/0	Validated
Klenquist 8123- 83100-25-ES	MONITORING MMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (SPAIN)	4776460	\$0127740 <b>6</b>	77.0.7	#221/221/0 0	A salitation of the salitation
&larquist 8123- 83100-26-SE	MONITORING IMMUNOLOGIC, EIEMATOLOGIC AND INFLAMMATORY DISEASES (SWEDEN)	47.75460	6/12/2000	7.00	4217210	A al (Calendar)
Klarquist 8123- 83100-27-CH	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (SWITZERLAND)	47.76468	### ##################################	103.2693	42172010	Validated
Kiarquist 8123- 83100-38-UK	MONTRAING BAMUKOLGGIC, HEMATOLGGIC AND BUIL AMMATORY DISEASES (UK)	477/6460	X X X	1033693	0102/12/8	Validated
Klanquist 8123- 831100-29-40	MONITORING IMMINOLOGIC. HEMATOLOGIC AND INFLAMMATORY DISEASES (JAPAN)	2010-90939	84127200 <del>4</del>			Pending
Klempales 8123- 831100-30-HK	MONITORING IMMINOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES					Pording

4.52.885 4.52.8.4

	(HOMG KONG)			***************************************		
Kimquist 8123- 83101-01-US	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS	**************************************	4/0/2/004			EXPIRED
Klarquist 8123- 83101-02-US	REAL TIME METHOD OF DETECTING ACUTE DETECTING ACUTE	179 67.10	4.20			EXPIRED
Klangurat 8123- 83101-03-PCC	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATCRY CONDITIONS (PCT)	PK:T71/S200S/01	\$000			NATIONAL PHASE FILINGS-AU, CA, EP, JP
Klanyuist 8123- 83101-04-AU	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (AUSTRALIA)	2005241415	4.852003			Petriking
Klanpaist 8123-	REAL TIME METHOD OF DETECTING ACTITE INFLAMMATORY CONDITIONS (CANADA)	# T	<b>6</b> 8.200			Pending
Kimpota 8123- 83101-06-87	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (EUROPE)	\$7776689.I	S C X	[5] 88 87	S 8 8 8 8 8	CELLS
Klanguist 8123-	A1.	7887.287	Š			Pending
Klampnist 2123-	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (U.S.)	88 88 88 88	\$000	1987 1987 1987	422/2008	CEP) SSSI
Kalmpust #125- 85101-09-13	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (U.S.)	\$	88 87 82 83 83 84			Akmedonied
Kalmpulet 8123- 83101-10-8E	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (BELGIUM)		8	[] \$ \$ \$ \$	8/18/2010	Validated
Kimpoist 8123- 83101-11-DK	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (DENMARK)	2776889.1	4882003	1788871	8/18/2010	Vigitidatked
Klarguist 8123-	REAL TIME METHOD OF	\$776689.3	4/8/2005	1756571	8/18/2010	Validated
			<i>w</i> .			

\$486672 V5/SQ

Patent Reel: 043746 Franc: 08252

			:	٠	•

688672.95533

83101-12-61	DETECTING ACUTE INFLAMMATORY CONDITIONS (FINLAND)					
Klarquist 8123- 83101-13-FR	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (FRANCE)	57766889.1	4/8/2003	1726571	\$/18/2010	Valkined
Klanquist 8123- \$3101-14-DE	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (ORRMANY)	\$77668W	4/8/2003	\$	0.02.813	Validated
Kairquist 8123- 83101-15-17	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (ITALY)	577/86891	\$ 200.8	1758571	8/18/20110	Validated
Kalmpulist 8123- 83101-16-LU	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (LUXEMBOURG)	68		E 28	8/18/2010	Validareed
Klarquist 8133- 83101-17-NI	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITTONS (WETHERLANDS)	5776489.1	88,700	1736571	8/18/2010 000	Validaked
&Larquist 8123- 83101-18-ES	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (SPAIN)	21766880	¥8.	<b>2</b>		Validared
&larquist 8133- 83101-19-SE	REAL TIME METHOD OF DELYCTING ACUTE INFLAMMATORY COMPITIONS (SWEDEN)	23 23 23 23 24 24 24 24 24 24 24 24 24 24 24 24 24	Š.	Ş	8/18/2010	Validated
&lerquita 8123- 83101-20-CH	REAL TIME METHOD OF DEFECTING ACUITE INFLAMMATORY CONDITIONS (SWITZERLAND)	37776689	Š	E \$200	011028118	V alitéased
Klarquist 8123- 83101-21-03	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (UNITED KINGDOM)				8/18/2110	V alitherized
Klanquisa 8123-	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (RPC)		2000			Peakling
Klampinst 8123-	REAL TIME METHOD OF					Portding

PATENT REEL: 043747 FRANCE: 02263

ø

C838/12 v3/5D

#3101-23-4fK DETECTING ACUTE INFLAMMATORY CONDITIONS (HOWG KOND)

PATENT REEL: 043746 FRANK: 08274

ike Status	2010 ISSUED (Apr-10-2024 + 184 days) days) 2014 Filed divisional directed to TPA	Maint response the Aug-12-2010 Requirement for maintd, response the Aug-12-2010 Aug-12-2010 Str.	Awarding coars	ABANDONED CONTROLLED	EXPIRED Converted to Utility
Issue Date	00 100 100 100 100 100 100 100 100 100	(Mar-29-2200)			
Patent No.	2007023810 3	20000			
Filing Date	747 0.220 747 747		\$ 0 \$ 0 \$ 0 \$ 0 \$ 0 \$ 0 \$ 0 \$ 0 \$ 0 \$ 0		76. And 20.
Appin. No.				manus allaba musikallaba	60/840.973
Myentors	Guchelsar, itendrik km. Huizinga, Tom Willem Johannes Academisch Ziekenhuis HODN LUMC	Gucheleer, Hendrik Jan; Huzinga, Tom Willem Johannes Academisch Ziekenhuis HOD,N LUMC	Guchelaar: Hendrik Jan. Huisingst, Tom Willear Johannes Academisch Ziekenhuis HODN LUMC	Not Available Leids Universitair Medisch Centrum	Hendrik Guebelsar. Gosda, et al.
****	OENETIC MARKERS FOR PROGNOSIS OF ANTIFOLATE TREATMENT EFFICACY	OENETIC MARKERS FOR PROGNOSIS OF ANTIFOLATE TREATMENT SPFICACY	OENETTC MARKERS FOR PROCNOSIS OF ANTIFOLATE TREATMENT EFFICACY	CEMETIC MARKERS FOR PROCNESS OF ANTIFOLATE TREATMENT EFFICACY	Pharmacogenetic method for prediction of the efficacy of methotresate monotherapy in
Cooley Docket No.	MARKER III (AMPDI, IITPA, [ATTC, MITR, MTRRI) COTTR BROOKISA PROPERTIESA PROPERTIESA PROPERTIESA PROPERTIESA PROPERTIESA PROPERTIESA PROPERTIESA PROPERTIESA	MARKER III	MARKER III CYPR- 036/00/5	MARKER III P9008184EP	MARKER IV MITHER (or optionally one

SCHEDULED

688872 y5/SD

	PENDING Awaiting examination	SHADOW FILE PENDING National Place deadline: 2009-02-28	SHADOW FILE ABANDONED	EXPIRED Converted to Utility, application	ISSUED Expires: May-10-3028 (Apri-06-3027 + 400
	Nov-20-3008				Apr-20-2010 Cer-25-2007
	7, 0018				7,702,409 2107024898 6
	Aug-28-	Aug. 22-	7008 2008 3008	April 10-2(0)6	A214-466-22(8)
·	WWW.	7 8 7 8 8 8 5 8 5 8 5 8	\$ \$ \$		<b>\$</b>
Zoikenhuiy H O D N. LUNC	Guckelaar; Hendrik Ian; Hutsinga, Yon Willem Johanus: Academisch Zekemhuis	Guchelum, Bendrik Ian Huizinga, Tom Willem Johannes Academisch Zoskenbuis H.O.D.N. LLIMC	Hendrik GUCHELAAR Accelemisch Ziekenhuis B.G.D.N.LUMC	Huizinga, Toni Willem Johannes; Van Der Helm-Van Mil, Ama Helena Maria	Huizinga, Tom Willem Johannes; Van Der Helm-Van Mil, Anna Helena
	A PHARMACDOENETIC METHOD FOR PREDICTION OF THE EFFICACY OF METHOTREXATE MONOTHERAPY IN RECENT. ONSET ARTHRITIS	A PHARMACOUENETIC METHOD FOR PREDICTION OF THE BFFICACY OF METHOTREXATE MONOTHERAPY IN RECENT: ONSET ARTHRITIS	A PHARMACOGENETIC METHOD FOR PREDICTION OF THE EFFICACY OF METHOTREXATE MOWOTHERAPY, IN RECENT.	SYSTEMS AND METHODS FOR PREDICTING AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOD ARTHRITIS	SYSTEMS AND METHOLS FOR PREDICTING AN INDIVIDUAL'S RISK OF DRIVELOPMO RHELIMATOLD
OAPR. OAPR. PSUICES	MARKER IV CYPR. 040/01US PROPR.017A	MARKER IV CYPR- U4001 WO F6010832PCT P_359HG102	MARKER 17 OCYTH. 046000EP P6010833EP P, 239HOUG2	RA ALGORITHM I(LUMC) PMOSKISSUS P 039THU	RA PREDICTION/ ALGORITHM

08/84/2/59/89

Patent Reel: 043747 Franc: 0229

03/5× Z/9889

days)   1st feec due: Apr-21- 2014	CLOSED/PCT PERIOD OVER National Phase deadine 2008-10-07 Instruction sent to LOMC to enter mational phase in Europe Canada Australia Fapari	ABA/NDOWED DOWNED
	# T T T T T T T T T T T T T T T T T T T	
		April 2008
	PCT/NL20	
Maria ACADEMISCH ZIEKENHUIS LEIDEN HODN. LUMC	Huizinga, Tom Willem Johannes; Van Der Helm-Van Miria Academisch Ziekenhuis HODN, LUMC	Inventors imavaliable Acidemisch Ziekenhuis Leiden
	SYSTEMS AND METHODS FOR FREDICTING AN BOOK DUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS	SYSTEMS AND METHODS FOR PREDICTING AN INDIVIDIAL S RISK OF DEVELOPING RHELINATOID ARTHRITS
CANK. BBWOLKS PROPROTEK	PREDICTION ALCORDINATION OF THE CONTRIBUTION O	RA ALGORITHON ALGORITHON PGOOR ISSEP P_GOSTHU

PATENT REEL: 043747 FRANE: 04007

## SCHEDULE E

Status	CLOSED  Since Instigue in: AU 2006261942 CA 2614101 SP 06762214 US (filing; receipt to be confirmed) Mestico (ffo be confirmed)	PENDING Undergoing preliminary examination Annuity due 2789-04-30 (fo be confirmed with Organise)	PENDING Awaiting coamination Amouty due 2009-06-27
Issue Unte	10-25 S. 23.007		
Patent No.	2007/400320 A3 7/400320 A3 A3	2	
Filling Date	\$ 500 \$ 500 \$ 500 \$ 500 \$ 500 \$ 500 \$ 500 \$ 500 \$ 500 \$ 500 \$ 500 \$ 500 \$ 500		<b>500</b>
Appla. No.	200 200 300 300 300 300 300 300 300 300	2002.00	2
Inventors	Barte, Holger Berg, Wigbert Organice Diagnostika	Burg, Holger Berg, Wighert Organise Diagnostica Grahiii	Burn, Holger Berg, Wigbort Organica Diagnostica Ombli
	METHOD FOR DIAGNASS ITCATING RHRUWATIC DISEASIES	METHOD FOR DIAGNOSTICATING RHEUMATIC DISEASES	METHOD FOR DIAGNOSTICATING REFEUMATIC DISEASES
Confey Docket No.	Organico (week-AMCV)	38 (S)	O Establish

### SCHEDULEF

		S S S S S S S S S S S S S S S S S S S		Patent No.	Issue Date	
METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHODS FOR OPTIMIZING METHODS FOR OPTIMIZING METHODS FOR OPTIMIZING METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHODS FOR OPTIMIZING METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHODS FOR OPTIMIZING METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHODS FOR OPTIMIZING METHODS FOR OPTIMIZEND METHODS FOR O		LS(10)	Aug. 13:2008	2500	Avg-486-2008	S Salutany
METHODS FOR OPTIMIZATION   Devicing, Thierry   12/191,286	2 23 2			7.82.	Sept-21-2003 Many-26-22005	Request for Determination of PLA filed Nov-02-2009 Expires: 2026-03-14 (2024-08-26 + 365 days) I" fee due Sep-13-2013 Oiveissanis filed (RFC-1, ATTC, and TS)
METHODS FOR OPTIMIZARG CLINICAL RESPONSIVENESS TO Methorical METHOTREXATE THERAPY USING METHOTREXATE THERAPY USING METHOTREXATE THERAPY USING METHOTREXATE THERAPY USING METHODS FOR OPTIMIZARG CLINICAL RESPONSIVENESS TO METHODS FOR OPTIMIZARG CLINICAL RESPONSIVENESS TO METABOLITE PROFILENCIAN DEVICES.	Dervieus Waltal. A Prometh Laboratsi	(2/191,286	Š	75. 24. 25. 26. 26. 26. 26. 26. 26. 26. 26. 26. 26	Aug. 46:-2203	PENDING Avening examination
METHODS FOR OPTIMIZING Devices, Thierry 2539953 CLINICAL RESPONSIVENESS TO Walsh Michael METHOTREXATE THERAPY USING Promothers	2 2 2 2	2 % 2 % 3 %	Aug. 27.28%			EXPIRED Entered mational stages: EP 0478.2148.9 CA 2559953
Laboratorios, inc.	2 83g	Š	Aug-27.2004			CCINSII NAME OF THE COLUMN TO
MARKER I METHODS FOR OPTIMIZING Dervicux, Thierry (94782348.9 Aug	Dervieu	04782348.9	Aug. 17-2004			PENDING

<u>'</u>Z

OTFICE ACTION RESPONSE FUED 729/2009 DIVISIONAL DUE	EXPIRED Conversed to Utility application	EXPIRED Converted to Utility application	Response to Non-Final Response to Non-Final Rejection filed Feb-22- 2010 Filed divisional directed to SHMT1 (efficacy) and	Awaiting geomination	PENDING Awaiting examination	EXPIRED Entered National Strages. AU 20002239279
			Dec-21-2006			
			2006/02/02/02/02/02/02/02/02/02/02/02/02/02/			
		94 - 73-78 0 - 73-78 0 - 73-78	Apr.25-3006	Aug-19-2108	Aug-19-2002	Apr-26-2016
		\$65 121 131 131 131 131 131 131 131 131 131	E	257 M 1/2 M	18/48/	PCTRUS2006/ 16246
Waish, Michael Prometheus Laboratories, Inc.	Dervicus, Thierry Smith, Katte M. Prometheus Laboratories Inc.	Dervieux, Thierry Prometheus Laburatories Inc.	Darvicas, Thiany Promedicus Laboratories fre.	Dervieux, Thierry Prometheus Laborateries Inc.	Dervieus, Thiorry Prometheus Laboratories Inc.	Dervieux, Tuiorry Prometheus Laboratories Inc.
CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACO-GENETICS	METHODS FOR EVALUATING RISK ASSOCIATED WITH METHOTREXATE THERAPY USING PHARMACOGENETICS	METHODS FOR MONTORING METHOTREXATE THERAPY USING PHARMACOGENOMIC AND METABOLITE MARKERS	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	METHODS OF PREDICTING METHORREXATE DIFFICACY AND TOXICITY	METHODS OF PREDICTING METHOTREXATE BFFICACY AND TOXICITY
C1. PR-03.802.00	MARKER II cefficiency MTHIRA SHIWIT: townsity, ATIC, TSER, and MS)	MARKER II CYPR-834/01US	CVPR-034/ra1/s	MARKER II CYPR-034/03(IS	MARKER II CYPROSIA04US	MARKER III CYPR-034/02WO

688672 v5/533

Patent Reel: 043746 Franc: 04080

CA 28/08/42#	EXAM REQUESTED	REQUIEST FOR EXAM DUB 4767011	EXAM REQUESTED	ABANDONED Abandoned por JA's email instruction (Oct-14-2009)	Expires: Jan-23-2025 (Aug-30-2022 + 877) 1st fee due Jul-22-2013	EXPIRED Research National Stages: AU 20013270448 CA 2409901 EP 027519344	ECGS TEREIO
					Mar-14-2005		97,77,800.0
					7.581.550 200040002134 1		3833277844 440
	Apr-36-2006	Apr-25-2008	Apr-36-200	Ş	### ### ### ###		Awg-28-2003
	203900239279	786,04734	0073170		90/700 700/700	2,33 2,33 2,33 2,33 2,33 3,33 3,33 3,33	2003223046
	Dervicus, Therry Prometheus Laboratorice Inc.	Dervieus, Thienry Prometheus Laboratorics, Inc.	Dervicus, Thierry Promethous Caburatories Inc.	Marcelletti, John F Dervieux, Thierry Simpson, Lynn A. Prometheus Laboratories, Inc.	Dervieux, Thienty, Richerson, Russell B. Prometheus Laboratorics, Inc.	Dervicus, Thierty Richerson, Russell, B. Prometheur Lahventeries, Inc.	Dervicux, Thierry Richerson, Russell, B. Premetheus Laborateries, Inc.
	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	METHODS OF PREDICTING METHOTREXATE BIFFICACY AND TOXICTY	METHODS OF PREDICTING METHOTIREXATE EFFICACY AND TOXICITY	BIOMARKERS, ASSOCIATED WITH RESPONSE TO CHEMOTHERAPY	METHOTREXATE METABOLITES	METHODS OF QUANTIFYING METHOTREXATE METABOLITES	METHOPS OF QUANTIFYING METHOPISEXATE METABOLITES
	MARKER II CYPR-13402AU	MARKER II CYPR-034/02CA	MARKER II CYFR-4344337P	MARKER V (CD30/CD26) CYPR-033/00/38	MTXPG I (CGM conversion) CYPR-036/9913	MTXPG I CYPR-030/03WO	MTXPG1 CYPR-030/maxU

ž

PENDING OFFICE ACTION RESPONSE FILED SEPENIO	PENDING OFFICE ACTION RESPONSE FLED 104/2009 DIVISIONAL DUE 4222011	Divisional of CYPR- 030/10AU OFFICE ACTION ISSUED RESPONSE DUE 10/19/2010	ESSUED  Expiration date: May-22-2021  (Mar-07-2023 + 76 days)  Ist fac paid  2nd fac due MI-26-2013	EXPIRED Entered National Stages: AU 2004-1971 1 EP 2005-508989 CA 2517709	ALLOWED AWAITING LETTERS PATENT
			Sco 2400.5 - 200 - 200.64 - 200 - 200.64		
	\$2.50 \$7.50	<b>8</b>		Ž	Mss-422-2004
1000000	7.75199.4	2009212943		PC11.88	2004219711
Dervieux, Thierry Richerson, Russell, B. Frometheus Laboratories, Inc.	Dervieux, Thierry Richerson, Russell, B. Prometheus Laboratories, inc.	Dervicus, Thierry Richerson, Russell, B. Premetheus Laboratories, Inc.	Dervieux, Thierry Richerson, Russell Prometteux Lateoratorics, Inc.	Dervieux, Thierry Rüberson, Russell Promethous Laboratories, Inc.	Dervicus, Thierry Richerson, Russell Promethesis
METHODS OF QUANTIFYING METHOTREXATE METABOLITES	METHODS OF QUANTIFYING METHOTREXATE METABOLITIES	METHODS OF QUANTIPYING METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITED	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES
OYTPR-038/08/CA	JOANA AND AND AND AND AND AND AND AND AND	MTMPG I CYPR-03000(AU	MTXPG 11 (MTXPG assay) CYPR-032/00US	MT24PG	MTXPG III CYPRA3200AU

C188602

PATENT REEL: 048746 FRANE: 04052

	EXAM REQUESTRID		REGISTERED	RECUSARRED.	CHARLE STORY	SOS LEGISTRES	MOS REGISTERED	000 AYGISTERED
			10/28/200		Š			10/28/2009
		\(\tilde{	8		\$ \$		ã S	1604303
		Mar-22.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2	Wii:-4(2,2)(04	Mar-02-2004	Mar-02, 200	Marr 422.22(1)	Marr-22, 22, 22, 23, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24	Mar-423-2044
	\$ 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	\$24716493. <b>₹</b>	1744 1848 1848 1848 1848 1848 1848 1848	Š Ž	04716483.4	1.04.71.84 1.04.05 1.04.05	04716493.4	04716493,4
Laboratories, Inc.	Dayloux, Thierry Richerson, Russell Promethous Laboratories, Inc.	Devetors, Theory Richorson, Russell Prometheus Laboratories, Inc.	Dervieux, Thleny Richerson, Russell Prometheus Laboratories, Inc.	Dervieux, Thierry Richargen, Russell Prometheus Laboratories, Inc.	Dervieux, Thiorry Ribberson, Russell Prometheus Labaratories, Inc.	Dervteux, Thierry Richerson, Russell Promethous Labomicnies, Inc.	Dervieux, Thierry Richerson, Russell Prometheus Laborateries, Inc.	Dervieux, Thierry
	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT
	MTXPG II CYPR-032/00CA	MTXPG II CYPR-032/00EP	MTXPG II CYPR-032/00BE	MTXPO II CYPR-612/06DK	MTXPG II CYPK-602/0001	MTXPG II CYPR-051/00FR	MTXPG II CYPR-533/00DE	MTXPG

Ç

	CHAST EXCED	REGISTER/CD	CENTER COST	REDISTERED.	CONTRACTOR OF THE CONTRACTOR O	RECORTER ED	PUM. Safeth	TAKE NO FURTHER ACTION TO BE ABANDONED	Divisional of CYPR- 032/00EP
	2787708	<b>8</b>	80000000000000000000000000000000000000	8	8007000	282383			
	94833	1664203		1604203		180/47833			
	2 2 2 2 3 3 4 3	Mar-02-2004	War-422-2004		## - 475 - 278 H	Mar-82-2004	Mar-02-2304	\$5.5 \$3.5 \$4.5 \$4.5 \$4.5 \$4.5 \$4.5 \$4.5 \$4.5 \$4	May-12-2004
	2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00	54716493.4	# 1	4.16499.14	1077	#116223.4 #	20102. 1	300 - 100 -	090134842
Printesheus Laboratories, Inc.	Dervleux, Thierry Richerxen, Russell Prometheus Laboratories, Inc.	Dervleux, Thierry Richerson, Russell Prumetheus Laboratories, Inc.	Depvleux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	Dervicus, Theory Richerson, Kussell Prometheus Laborataries, Inc.	Dervieux, Thierry Richerson, Russell Prometheus Laboratorius, Inc	Dervieux, Thiony Richerson, Russell Promedieus Laboraiories, Inc.	Dervieux, Thierty Richerson, Russell Prometheus Laboratories, Inc	Dervicus, Thierry Richerson, Russell Prometheus Laboratories, Inc.	Dervieus, Thienry Richerson, Russell
	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITIES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREX ATE METABOLITES
	MTXPG II CYPR-032/00LU	MTXPG II CYPR-032/00ML	MTXPG11 CYPR-032/00EX	MTKPO II CVPR-032/08/SE	MTXPG II CYPR-032/00/CH	MTXPG II CYPR-032/00GB	MTXPG II CYPK-032/00J#K	MTXPG II CYPR-032/001P	MTXPG II CYPR-032,01EP

S.

PUBLISHED	SADING	EXPIRED Converted To Utility Application	[SSUED Expires: Oct-15-2027 (Dm-13-3025 + 854 days) ["fee due: App-14-2014	PENDING Availing examination	EXPTRED Entered National Stages: AU 2005237949 CA 2591610 EP 05762644.2 ###################################	PENDING OFFICE ACTION RESPONSE PLEED
			Apr. 13-2010 Mar-16-2006			
			7,695,908			
	Mar-02-2004	7-200-45-700-500-45-700-45-700-45-700-45-700-45-700-50-50-50-50-50-50-50-50-50-50-50-50-5	S	Feb-02-2010	######################################	fare (4-2013
	(0.103.341	60/380, 141	11/152,128	88 % 2002	PC(1/1/82)00/2	2391610
Prometheus Latoratories, Inc.	Dervicas, Thierry Richerson, Russell Primetheus Labormortes, Inc.	Dervieux, Thierry Prometheus Laboratories, Inc.	Dervieux, Thierty Promethous Laboratories, Inc.	Dervieux, Thierry Prometheus Laboratories, Inc.	Derweus, Thierry Frometheus Laboratoreis, Inc.	Dervicas, Thierry Prometheus Laboratoreis, Inc.
	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	METHODS FOR PREDICTING METHOTREXATE POLYGLITAMATE LEVELS USING PHARMACOGENETICS	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACOGENETICS	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACOGENETICS	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEELS USING PHARMACOGENETICS	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEELS USING PHARMACO-GENETICS
	MTXPG III CYPR-032/01HK	MIT TO THE STATE OF THE STATE O	MTXPG JIII CYYPRAZSANIUS	MTXPG111 CYPR-0200011S	MTXPG III CYPR-029/01/8/0	MTXPG III CYPR-02901EP

3

	DIVISIONAL DUE	ABANDONED	EXAM REQUESTED	OFFICE ACTION ISSUED Response Due 1/20/2011	ABANDONED	ABANDCINIED
					700 60 700 700 700 700 700 700 700 700 7	Apr-26-2007
-					3 0 0 0 0 0 0 0	20070093497
		Jun-14-2005	Jun-14-2003	**************************************	Mar-06-2003	Oct-31-200%
		316642	2,591,610	2008257940	102264,3551	416383,216
		Dervieux, Unierry Promethoux Laboratoreis, Inc.	Dervicus, Phierry Prometheus Laioratoreis, Inc.	Dervieux, Thierry Promethons Exboratoreis, Inc.	Walsh, Michael I., Prometheus Laboracories, Inc.	Weileh, Michael J., Prometheus Labonitories, Inc.
		METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEELS USING PHARMACO-GENETICS	METHODS FOR PREDICTING NETHOTHEXATE POLYGLUTAMATE LEELS USING PHARMACO-GENETICS	METHODS FOR PREDICTIMS METHOTREXATE POLYGLUTAMATE LEELS USING PHARMACO-GENETICS	METHOTREXATE COMPLIANCE PACKAGING	METROTREXATE COMPLIANCE PACKAGING
***************************************		MTXPG III CYPR-429/01/P	MTXPG III CYPR-029/n (CA	MTXPO III CYPR-UZBAUI ALL	Compliance Packaging CYPR-031/00US	Compliance Packaging CYPR-031/01US

..... ......